{
    "body": "Signaling of which pathways is inhibited by Dupilumab?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25006719", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26454361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25214796", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25645542", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26308331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27525671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27637004", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25542094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26967382", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27223113", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26457448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23688323", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24275927"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0037083", 
            "o": "http://linkedlifedata.com/resource/umls/label/A7662356"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A7662356", 
            "o": "Signaling"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C1710082", 
            "o": "http://linkedlifedata.com/resource/umls/label/A17472893"
        }
    ], 
    "ideal_answer": [
        "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling. It is used for treatment of atopic or allergic diseases."
    ], 
    "exact_answer": [
        [
            "interleukin-4"
        ], 
        [
            "interleukin-13"
        ]
    ], 
    "concepts": [
        "http://amigo.geneontology.org/amigo/term/GO:0023052", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015398"
    ], 
    "type": "list", 
    "id": "5880b2a6c872c95565000004", 
    "snippets": [
        {
            "offsetInBeginSection": 724, 
            "offsetInEndSection": 1170, 
            "text": "This study reviewed all studies about any roles of IL-4 that can directly and indirectly be played in the development of pemphigus and IL-4 inhibition with interferons and dupilumab therapy were introduced as a novel pemphigus treatment for patients who are in relapse phase of the disease. Dupilumab was also introduced as a possible treatment for patients with severe pemphigus. It can directly inhibit IL-4 by targeting IL-4 \u03b1-chain receptor. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26440137", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 149, 
            "offsetInEndSection": 276, 
            "text": "OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26836729", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 187, 
            "text": "BACKGROUND: Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 936, 
            "offsetInEndSection": 1158, 
            "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1051, 
            "offsetInEndSection": 1337, 
            "text": "Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor \u03b1-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27497276", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 249, 
            "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 450, 
            "offsetInEndSection": 614, 
            "text": "The world's first prospective controlled studies with the biologic human anti-IL4R antibody dupilumab for the indication \"atopic dermatitis\" were published in 2014.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25645542", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 708, 
            "offsetInEndSection": 803, 
            "text": "An IL-4R antagonist, dupilumab, is the first drug that shows great promise in phase II trials. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25542094", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 625, 
            "offsetInEndSection": 818, 
            "text": "Dupilumab, a humanized monoclonal antibody to the interteukin-4R is the first antibody (i.e. 'biological') with published efficacy shown in controlled prospective studies in atopic dermatitis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26308331", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 90, 
            "offsetInEndSection": 271, 
            "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 240, 
            "offsetInEndSection": 368, 
            "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 242, 
            "text": "Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26454361", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 248, 
            "text": "Background Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690741", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 742, 
            "offsetInEndSection": 974, 
            "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 174, 
            "text": "Dupilumab, a fully human anti-interleukin-4 receptor \u03b1 monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130691", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 91, 
            "offsetInEndSection": 271, 
            "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 101, 
            "offsetInEndSection": 684, 
            "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \ufffd, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 91, 
            "offsetInEndSection": 272, 
            "text": "Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor \u03b1 subunit that blocks the signaling of IL-4 and IL-13, both key cytokines in Th2-mediated pathways.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 242, 
            "offsetInEndSection": 370, 
            "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 746, 
            "offsetInEndSection": 978, 
            "text": "The robust effects of dupilumab on skin inflammation and pruritus confirm the pathogenic role of IL-4 and IL-13 signaling in adult AD, and further support the application of Th2 cytokine antagonists in the treatment of this disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598956", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 101, 
            "offsetInEndSection": 683, 
            "text": "In early-phase trials, dupilumab, a fully human mAb targeting IL-4 receptor \u00e1, markedly improved disease activity, but the effect of IL-4/IL-13 blockade on AD at the molecular level has not been characterized.OBJECTIVES: We sought to evaluate dupilumab modulation of the AD molecular signature.METHODS: We performed transcriptomic analyses of pretreatment and posttreatment skin biopsy specimens from patients with moderate-to-severe AD treated weekly with 150 or 300 mg of dupilumab or placebo.RESULTS: Exacerbation of the AD transcriptome was observed in placebo-treated patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25482871", 
            "endSection": "abstract"
        }
    ]
}